C WorldWide Group Holding A S increased its position in shares of Horizon Pharma PLC (NASDAQ:HZNP) by 17.4% during the second quarter, Holdings Channel reports. The institutional investor owned 388,284 shares of the biopharmaceutical company’s stock after buying an additional 57,575 shares during the period. C WorldWide Group Holding A S’s holdings in Horizon Pharma PLC were worth $4,609,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. BlackRock Inc. increased its stake in shares of Horizon Pharma PLC by 68,479.5% in the first quarter. BlackRock Inc. now owns 13,261,212 shares of the biopharmaceutical company’s stock worth $196,001,000 after buying an additional 13,241,875 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Horizon Pharma PLC by 4.1% in the first quarter. Vanguard Group Inc. now owns 12,749,275 shares of the biopharmaceutical company’s stock worth $188,434,000 after buying an additional 506,596 shares in the last quarter. Janus Capital Management LLC increased its stake in shares of Horizon Pharma PLC by 19.4% in the first quarter. Janus Capital Management LLC now owns 4,409,717 shares of the biopharmaceutical company’s stock worth $65,173,000 after buying an additional 717,643 shares in the last quarter. State Street Corp increased its stake in shares of Horizon Pharma PLC by 1.0% in the first quarter. State Street Corp now owns 4,382,120 shares of the biopharmaceutical company’s stock worth $64,766,000 after buying an additional 42,142 shares in the last quarter. Finally, Alliancebernstein L.P. increased its stake in shares of Horizon Pharma PLC by 14.8% in the first quarter. Alliancebernstein L.P. now owns 4,064,995 shares of the biopharmaceutical company’s stock worth $60,081,000 after buying an additional 525,486 shares in the last quarter. Institutional investors own 82.95% of the company’s stock.

Horizon Pharma PLC (NASDAQ:HZNP) opened at 11.54 on Friday. The stock’s market capitalization is $1.89 billion. Horizon Pharma PLC has a 52 week low of $9.45 and a 52 week high of $23.44. The firm has a 50 day moving average of $12.44 and a 200-day moving average of $13.69.

Horizon Pharma PLC (NASDAQ:HZNP) last announced its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.12 by $0.29. The firm had revenue of $289.51 million during the quarter, compared to analyst estimates of $237.01 million. Horizon Pharma PLC had a negative net margin of 42.40% and a positive return on equity of 22.85%. Horizon Pharma PLC’s quarterly revenue was up 12.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.56 earnings per share. On average, equities analysts predict that Horizon Pharma PLC will post $1.07 EPS for the current year.

Horizon Pharma PLC announced that its Board of Directors has authorized a stock buyback plan on Monday, May 8th that permits the company to repurchase 1,000% of outstanding shares. This repurchase authorization permits the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

TRADEMARK VIOLATION NOTICE: This article was first posted by Watch List News and is the property of of Watch List News. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.watchlistnews.com/c-worldwide-group-holding-a-s-raises-position-in-horizon-pharma-plc-nasdaqhznp/1474459.html.

HZNP has been the topic of a number of research reports. Piper Jaffray Companies set a $17.00 price target on shares of Horizon Pharma PLC and gave the company a “buy” rating in a report on Tuesday, July 25th. BidaskClub upgraded shares of Horizon Pharma PLC from a “hold” rating to a “buy” rating in a report on Saturday, June 24th. Citigroup Inc. reduced their price target on shares of Horizon Pharma PLC from $20.00 to $13.00 and set a “buy” rating on the stock in a report on Tuesday, May 9th. Cantor Fitzgerald set a $13.00 price target on shares of Horizon Pharma PLC and gave the company a “buy” rating in a report on Monday, July 31st. Finally, UBS AG set a $16.00 price target on shares of Horizon Pharma PLC and gave the company a “buy” rating in a report on Tuesday. Five research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $19.46.

About Horizon Pharma PLC

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).

Institutional Ownership by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.